Find Solriamfetol Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

KDMF

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Jzp-110 hydrochloride, 178429-65-7, Solriamfetol (hydrochloride), K7ro88sp7a, Solriamfetol hydrochloride [usan], Solriamfetol hydrochloride (usan)
Molecular Formula
C10H15ClN2O2
Molecular Weight
230.69  g/mol
InChI Key
KAOVAAHCFNYXNJ-SBSPUUFOSA-N
FDA UNII
K7RO88SP7A

Solriamfetol Hydrochloride
1 2D Structure

Solriamfetol Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(2R)-2-amino-3-phenylpropyl] carbamate;hydrochloride
2.1.2 InChI
InChI=1S/C10H14N2O2.ClH/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8;/h1-5,9H,6-7,11H2,(H2,12,13);1H/t9-;/m1./s1
2.1.3 InChI Key
KAOVAAHCFNYXNJ-SBSPUUFOSA-N
2.1.4 Canonical SMILES
C1=CC=C(C=C1)CC(COC(=O)N)N.Cl
2.1.5 Isomeric SMILES
C1=CC=C(C=C1)C[C@H](COC(=O)N)N.Cl
2.2 Other Identifiers
2.2.1 UNII
K7RO88SP7A
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (2r)-2-amino-3-phenylpropyl Carbamate

2. (r)-2-amino-3-phenylpropylcarbamate Hydrochloride

3. Adx-n05

4. Benzenepropanol, Beta-amino-, Carbamate (ester), (betar)-

5. Jzp-110

6. Solriamfetol

7. Sunosi

2.3.2 Depositor-Supplied Synonyms

1. Jzp-110 Hydrochloride

2. 178429-65-7

3. Solriamfetol (hydrochloride)

4. K7ro88sp7a

5. Solriamfetol Hydrochloride [usan]

6. Solriamfetol Hydrochloride (usan)

7. R-228060

8. Sunosi (tn)

9. Unii-k7ro88sp7a

10. Adx-n05 Hydrochloride

11. Ykp-10a Hydrochloride

12. Schembl8430382

13. Adx-n-05 Hydrochloride

14. Skl-n-05 Hydrochloride

15. Chembl4297212

16. Dtxsid101027927

17. R-228060 Hydrochloride

18. Hy-109043a

19. Solriamfetol Hydrochloride [mi]

20. Solriamfetol Hydrochloride [who-dd]

21. Cs-0112102

22. O-carbamoyl-(d)-phenylalaninol Hydrochloride

23. D11328

24. Solriamfetol Hydrochloride [orange Book]

25. (d)-o-carbamoylphenylalaninol Hydrochloride Salt

26. R228060;jzp-110;adx-n05;skl-n05;ykp-10

27. (2r)-2-amino-3-phenylpropyl Carbamate, Monohydrochloride

28. (betar)-beta-amino-benzenepropanol 1-carbamate Hydrochloride (1:1)

29. (r)-(+)-2-amino-1-carbamoyloxy-3-phenylpropane Hydrochloride

30. Benzenepropanol, .beta.-amino-, 1-carbamate, Hydrochloride (1:1), (.beta.r)-

31. 561069-23-6

2.4 Create Date
2012-11-30
3 Chemical and Physical Properties
Molecular Weight 230.69 g/mol
Molecular Formula C10H15ClN2O2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count3
Rotatable Bond Count5
Exact Mass230.0822054 g/mol
Monoisotopic Mass230.0822054 g/mol
Topological Polar Surface Area78.3 Ų
Heavy Atom Count15
Formal Charge0
Complexity179
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).

Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).


5 Pharmacology and Biochemistry
5.1 ATC Code

N06BA14


API SUPPLIERS

read-more
read-more

01

Inke S.A

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInke S.A: APIs manufacturing plant.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Inke Company Banner

02

Egis Pharmaceuticals PLC

Hungary

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Egis Pharmaceuticals

03

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West
Not Confirmed
arrow

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International US West
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

04

Alivus Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West
Not Confirmed
arrow

Alivus Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International US West
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT arrow-down
blank

05

Hikma Pharmaceuticals

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International US West
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

06

Unichem Laboratories Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West
Not Confirmed
arrow

Unichem Laboratories Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International US West
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

07

Alkem Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West
Not Confirmed
arrow

Alkem Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International US West
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International US West
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

09

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International US West
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

10

Glenmark Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West
Not Confirmed
arrow

Glenmark Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International US West
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

BioProcess International US West
Not Confirmed

01

BioProcess International US West
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-12-16

Pay. Date : 2022-11-14

DMF Number : 34741

Submission : 2020-03-31

Status : Active

Type : II

blank

02

Alkem Laboratories Ltd

India

USDMF

arrow
BioProcess International US West
Not Confirmed

02

Alkem Laboratories Ltd

India
arrow
BioProcess International US West
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-02-15

Pay. Date : 2023-02-03

DMF Number : 36951

Submission : 2022-03-28

Status : Active

Type : II

blank

03

BioProcess International
Not Confirmed

03

BioProcess International
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-04-28

Pay. Date : 2023-01-09

DMF Number : 37929

Submission : 2023-01-10

Status : Active

Type : II

blank

04

Hetero Drugs Ltd

India

USDMF

arrow
BioProcess International US West
Not Confirmed

04

BioProcess International US West
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-05-16

Pay. Date : 2023-04-12

DMF Number : 38280

Submission : 2023-04-18

Status : Active

Type : II

blank

05

Hikma Pharmaceuticals Llc

United Kingdom

USDMF

arrow
BioProcess International US West
Not Confirmed

05

Hikma Pharmaceuticals Llc

United Kingdom
arrow
BioProcess International US West
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-04-04

Pay. Date : 2022-12-19

DMF Number : 37548

Submission : 2022-12-28

Status : Active

Type : II

blank

06

BioProcess International US West
Not Confirmed

06

BioProcess International US West
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-03-16

Pay. Date : 2023-01-25

DMF Number : 36949

Submission : 2022-03-30

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

Solriamfetol Hydrochloride IH

Date of Issue : 2023-11-28

Valid Till : 2026-11-28

Written Confirmation Number : WC-0310

Address of the Firm : Plot No. Z-103/l, Dahej SEZ, Phase II, Dahej, Dist-Bharuch, Gujarat, India

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL HYDROCHLORIDE

NDC Package Code : 59651-756

Start Marketing Date : 2023-11-07

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

02

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

NDC Package Code : 65977-0140

Start Marketing Date : 2019-12-17

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL HYDROCHLORIDE

NDC Package Code : 53747-100

Start Marketing Date : 2022-03-30

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

Alivus Life Sciences Limited

Country
BioProcess International US West
Not Confirmed
arrow

Alivus Life Sciences Limited

Country
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL HYDROCHLORIDE

NDC Package Code : 66039-953

Start Marketing Date : 2020-09-08

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Inke S.A

Spain
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInke S.A: APIs manufacturing plant.

Flag Spain
Digital Content Digital Content

Solriamfetol Hydrochloride

About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...

Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse therapeutic areas, but mainly for use in Respiratory. Inke has been successfully inspected by every major global authority for a wide array of products (last inspection on behalf of US-FDA was in 2023). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Inke Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Solriamfetol

About the Company : Egis, part of the Servier Group, manufactures products at three EMA-, FDA-, ANVISA-, PMDA-, and KFDA-certified sites in Hungary. It sells branded products in 18 countries and reach...

Egis, part of the Servier Group, manufactures products at three EMA-, FDA-, ANVISA-, PMDA-, and KFDA-certified sites in Hungary. It sells branded products in 18 countries and reaches 100 countries with its APIs and finished products. Egis focuses on cardiovascular and central nervous system diseases, with offerings in diabetology, dermatology, and wound care. Its R&D emphasizes high-quality, value-added branded generics, and since 2023, Egis also provides CDMO and CMO services. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Egis Pharmaceuticals

03

Alkem Laboratories

India
BioProcess International
Not Confirmed
arrow

Alkem Laboratories

India
arrow
BioProcess International
Not Confirmed

Solriamfetol Hydrochloride

About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...

Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 40 countries. 29% of our revenue is generated via offshore sales and it has consistently been ranked amongst the top ten pharmaceutical companies in India. They have 20 manufacturing facilities at multiple locations in India and the United States of America.
blank

04

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Solriamfetol Hydrochloride

About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
blank

05

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Solriamfetol Hydrochloride

About the Company : Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in mark...

Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in markets across emerging economies including India. The generics business services the requirements of developed markets like US and Western Europe. Our API business sells products in over 65 countries including the US, various countries in the EU, South America and India. With 15 manufacturing facilities and 3 R&D centers dedicated to the goal of enriching lives across the globe.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738693800,"product":"SOLRIAMFETOL HYDROCHLORIDE","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"NOUCOR HEALTH S A","customerCountry":"SPAIN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2500","totalValueFC":"2289.6","currency":"USD","unitRateINR":199114.73000000001,"date":"05-Feb-2025","totalValueINR":"199114.73","totalValueInUsd":"2289.6","indian_port":"Hyderabad Air","hs_no":"29242990","bill_no":"7894368","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1756060200,"product":"SOLRIAMFETOL HYDROCHLORIDE","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"UNDISCLOSED","customerCountry":"SPAIN","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"2500","totalValueFC":"61012.5","currency":"USD","unitRateINR":213591.89079999999,"date":"25-Aug-2025","totalValueINR":"5339797.27","totalValueInUsd":"61012.5","indian_port":"Hyderabad Air","hs_no":"29242990","bill_no":"4741366","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641148200,"product":"SOLRIAMFETOL HYDROCHLORIDE [DRUG LICENCE NO : TL\/HZ\/20\/002745 DT : 25.09.2020]","address":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST","city":"MUMBAI,MAHARASHTRA","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"#N\/A","customer":"NOVARTIS HEALTHCARE PRIVATE LTD","customerCountry":"INDIA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"3000","totalValueFC":"31069.8","currency":"USD","unitRateINR":"231450","date":"03-Jan-2022","totalValueINR":"2314500","totalValueInUsd":"31069.8","indian_port":"HYDERABAD AIR","hs_no":"29242990","bill_no":"6936184","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST"}]
03-Jan-2022
25-Aug-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for major depressive disorder (MDD) with and without severe excessive daytime sleepiness.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 01, 2025

blank

01

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for major depressive disorder (MDD) with and without severe excessive daytime sleepiness.

Product Name : Sunosi

Product Type : Controlled Substance

Upfront Cash : Inapplicable

April 01, 2025

blank

Details:

Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for the treatment of attention deficit hyperactivity disorder.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 25, 2025

blank

02

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for the treatment of attention deficit hyperactivity disorder.

Product Name : Sunosi

Product Type : Controlled Substance

Upfront Cash : Inapplicable

March 25, 2025

blank

Details:

Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Binge-Eating Disorder.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 17, 2025

blank

03

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Binge-Eating Disorder.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

March 17, 2025

blank

Details:

Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Disorders of Excessive Somnolence.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Sleep Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 23, 2024

blank

04

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Disorders of Excessive Somnolence.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

August 23, 2024

blank

Details:

Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Sleep Brand Name: Sunosi

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 29, 2024

blank

05

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy.

Product Name : Sunosi

Product Type : Controlled Substance

Upfront Cash : Inapplicable

May 29, 2024

blank

Details:

Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Binge-Eating Disorder.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 14, 2024

blank

06

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Binge-Eating Disorder.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

May 14, 2024

blank

Details:

Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 11, 2024

blank

07

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

April 11, 2024

blank

Details:

Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of binge eating disorder.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 01, 2024

blank

08

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of binge eating disorder.

Product Name : Sunosi

Product Type : Controlled Substance

Upfront Cash : Inapplicable

April 01, 2024

blank

Details:

Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of major depressive disorder.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 19, 2024

blank

09

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of major depressive disorder.

Product Name : Sunosi

Product Type : Controlled Substance

Upfront Cash : Inapplicable

March 19, 2024

blank
  • Development Update

Details:

Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Sclerosis.


Lead Product(s): Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Controlled Substance

Sponsor: National Multiple Sclerosis Society | Axsome Therapeutics

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 14, 2023

blank

10

Johns Hopkins University

Country
arrow
BioProcess International US West
Not Confirmed

Johns Hopkins University

Country
arrow
BioProcess International US West
Not Confirmed

Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable

Therapeutic Area : Neurology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : National Multiple Sclerosis Society | Axsome Therapeutics

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Solriamfetol is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Sclerosis.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

December 14, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

ATNAHS PHARMA UK LIMITED

United Kingdom
BioProcess International US West
Not Confirmed
arrow

ATNAHS PHARMA UK LIMITED

United Kingdom
arrow
BioProcess International US West
Not Confirmed

Sunny Day

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date : 22/03/2022

Application Number : 68177

Regulatory Info : Allowed

Registration Country : Switzerland

blank

02

ATNAHS PHARMA UK LIMITED

United Kingdom
BioProcess International US West
Not Confirmed
arrow

ATNAHS PHARMA UK LIMITED

United Kingdom
arrow
BioProcess International US West
Not Confirmed

Sunny Day

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 22/03/2022

Application Number : 68177

Regulatory Info : Allowed

Registration Country : Switzerland

blank

03

ATNAHS PHARMA UK LIMITED

United Kingdom
BioProcess International US West
Not Confirmed
arrow

ATNAHS PHARMA UK LIMITED

United Kingdom
arrow
BioProcess International US West
Not Confirmed

Solriamfetol hydrochloride

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

04

ATNAHS PHARMA UK LIMITED

United Kingdom
BioProcess International US West
Not Confirmed
arrow

ATNAHS PHARMA UK LIMITED

United Kingdom
arrow
BioProcess International US West
Not Confirmed

Solriamfetol hydrochloride

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

05

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 75MG

Packaging :

Approval Date :

Application Number : 218725

Regulatory Info :

Registration Country : USA

blank

06

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number : 218725

Regulatory Info :

Registration Country : USA

blank

07

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL HYDROCHLORIDE

Brand Name : SUNOSI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 75MG BASE

Packaging :

Approval Date : 2019-06-17

Application Number : 211230

Regulatory Info : RX

Registration Country : USA

blank

08

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL HYDROCHLORIDE

Brand Name : SUNOSI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 150MG BASE

Packaging :

Approval Date : 2019-06-17

Application Number : 211230

Regulatory Info : RX

Registration Country : USA

blank

09

Hetero Drugs

India
BioProcess International US West
Not Confirmed
arrow

Hetero Drugs

India
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 300MG

Packaging :

Approval Date :

Application Number : 218654

Regulatory Info :

Registration Country : USA

blank

10

Hetero Drugs

India
BioProcess International US West
Not Confirmed
arrow

Hetero Drugs

India
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 75MG

Packaging :

Approval Date :

Application Number : 218654

Regulatory Info :

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 75MG

Approval Date :

Application Number : 218725

RX/OTC/DISCN :

RLD :

TE Code :

blank

02

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 150MG

Approval Date :

Application Number : 218725

RX/OTC/DISCN :

RLD :

TE Code :

blank

03

AXSOME MALTA

U.S.A
BioProcess International US West
Not Confirmed
arrow

AXSOME MALTA

U.S.A
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL HYDROCHLORIDE

Brand Name : SUNOSI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 75MG BASE

Approval Date : 2019-06-17

Application Number : 211230

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

04

AXSOME MALTA

U.S.A
BioProcess International US West
Not Confirmed
arrow

AXSOME MALTA

U.S.A
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL HYDROCHLORIDE

Brand Name : SUNOSI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 150MG BASE

Approval Date : 2019-06-17

Application Number : 211230

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

05

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 300MG

Approval Date :

Application Number : 218654

RX/OTC/DISCN :

RLD :

TE Code :

blank

06

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 75MG

Approval Date :

Application Number : 218654

RX/OTC/DISCN :

RLD :

TE Code :

blank

07

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL

Brand Name : SOLRIAMFETOL

Dosage Form : TABLET

Dosage Strength : 150MG

Approval Date :

Application Number : 218654

RX/OTC/DISCN :

RLD :

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

Sunny Day

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date : 22/03/2022

Application Number : 68177

Regulatory Info : Allowed

Registration Country : Switzerland

blank

02

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

Solriamfetol hydrochloride

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

03

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

Solriamfetol hydrochloride

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

04

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

Solriamfetol Hydrochloride

Brand Name : Sunrise

Dosage Form : Film Coated Tablet

Dosage Strength : 75MG

Packaging :

Approval Date : 12-02-2021

Application Number : 1191408002

Regulatory Info : Authorized

Registration Country : Spain

blank

05

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

Solriamfetol Hydrochloride

Brand Name : Sunrise

Dosage Form : Film Coated Tablet

Dosage Strength : 150MG

Packaging :

Approval Date : 12-02-2021

Application Number : 1191408007

Regulatory Info : Authorized

Registration Country : Spain

blank

06

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

Solriamfetol Hydrochloride

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 16-01-2020

Application Number : 28106191518

Regulatory Info : Prescription

Registration Country : Denmark

blank

07

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

Solriamfetol Hydrochloride

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date : 16-01-2020

Application Number : 28106191418

Regulatory Info : Prescription

Registration Country : Denmark

blank

08

Atnahs Pharma Netherlands B.V.

Country
BioProcess International US West
Not Confirmed
arrow

Atnahs Pharma Netherlands B.V.

Country
arrow
BioProcess International US West
Not Confirmed

Solriamfetol

Brand Name : Sunosi

Dosage Form : Film-Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

09

Atnahs Pharma Netherlands B.V.

Country
BioProcess International US West
Not Confirmed
arrow

Atnahs Pharma Netherlands B.V.

Country
arrow
BioProcess International US West
Not Confirmed

Solriamfetol

Brand Name : Sunosi

Dosage Form : Film-Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

10

Atnahs Pharma Netherlands B.V.

Country
BioProcess International US West
Not Confirmed
arrow

Atnahs Pharma Netherlands B.V.

Country
arrow
BioProcess International US West
Not Confirmed

Solriamfetol Hydrochloride

Brand Name : Sunosi

Dosage Form : Film Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date : 16-01-2020

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL (SOLRIAMFETOL HYDROCHLORIDE)

Brand Name : SUNOSI

Dosage Form : TABLET

Dosage Strength : 75MG

Packaging :

Approval Date :

Application Number : 2515814

Regulatory Info : Prescription

Registration Country : Canada

blank

02

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

SOLRIAMFETOL (SOLRIAMFETOL HYDROCHLORIDE)

Brand Name : SUNOSI

Dosage Form : TABLET

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number : 2515822

Regulatory Info : Prescription

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 178429-65-7 / Solriamfetol Hydrochloride API manufacturers, exporters & distributors?

Solriamfetol Hydrochloride manufacturers, exporters & distributors 1

37

PharmaCompass offers a list of Solriamfetol Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Solriamfetol Hydrochloride manufacturer or Solriamfetol Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Solriamfetol Hydrochloride manufacturer or Solriamfetol Hydrochloride supplier.

PharmaCompass also assists you with knowing the Solriamfetol Hydrochloride API Price utilized in the formulation of products. Solriamfetol Hydrochloride API Price is not always fixed or binding as the Solriamfetol Hydrochloride Price is obtained through a variety of data sources. The Solriamfetol Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Solriamfetol Hydrochloride

Synonyms

Jzp-110 hydrochloride, 178429-65-7, Solriamfetol (hydrochloride), K7ro88sp7a, Solriamfetol hydrochloride [usan], Solriamfetol hydrochloride (usan)

Cas Number

178429-65-7

Unique Ingredient Identifier (UNII)

K7RO88SP7A

Solriamfetol Manufacturers

A Solriamfetol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Solriamfetol, including repackagers and relabelers. The FDA regulates Solriamfetol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Solriamfetol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Solriamfetol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Solriamfetol Suppliers

A Solriamfetol supplier is an individual or a company that provides Solriamfetol active pharmaceutical ingredient (API) or Solriamfetol finished formulations upon request. The Solriamfetol suppliers may include Solriamfetol API manufacturers, exporters, distributors and traders.

click here to find a list of Solriamfetol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Solriamfetol USDMF

A Solriamfetol DMF (Drug Master File) is a document detailing the whole manufacturing process of Solriamfetol active pharmaceutical ingredient (API) in detail. Different forms of Solriamfetol DMFs exist exist since differing nations have different regulations, such as Solriamfetol USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Solriamfetol DMF submitted to regulatory agencies in the US is known as a USDMF. Solriamfetol USDMF includes data on Solriamfetol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Solriamfetol USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Solriamfetol suppliers with USDMF on PharmaCompass.

Solriamfetol WC

A Solriamfetol written confirmation (Solriamfetol WC) is an official document issued by a regulatory agency to a Solriamfetol manufacturer, verifying that the manufacturing facility of a Solriamfetol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Solriamfetol APIs or Solriamfetol finished pharmaceutical products to another nation, regulatory agencies frequently require a Solriamfetol WC (written confirmation) as part of the regulatory process.

click here to find a list of Solriamfetol suppliers with Written Confirmation (WC) on PharmaCompass.

Solriamfetol NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Solriamfetol as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Solriamfetol API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Solriamfetol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Solriamfetol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Solriamfetol NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Solriamfetol suppliers with NDC on PharmaCompass.

Solriamfetol GMP

Solriamfetol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Solriamfetol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Solriamfetol GMP manufacturer or Solriamfetol GMP API supplier for your needs.

Solriamfetol CoA

A Solriamfetol CoA (Certificate of Analysis) is a formal document that attests to Solriamfetol's compliance with Solriamfetol specifications and serves as a tool for batch-level quality control.

Solriamfetol CoA mostly includes findings from lab analyses of a specific batch. For each Solriamfetol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Solriamfetol may be tested according to a variety of international standards, such as European Pharmacopoeia (Solriamfetol EP), Solriamfetol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Solriamfetol USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty